Literature DB >> 54744

Cyclic adenosine monophosphate, ventricular fibrillation, and antiarrhythmic drugs.

T Podzuweit, W F Lubbe, L H Opie.   

Abstract

It is proposed that the development of ventricular fibrillation in the context of ischaemic heart-disease and myocardial infarction can be related to accumulation of cyclic adenosine 3',5' monophosphate (A.M.P.) in the ischaemic zone. The known electrophysiological and metabolic actions of cyclic A.M.P. are consonant with the hypothesis, which also provides a framework for the better understanding of the action of antiarrhythmic drugs.

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 54744     DOI： 10.1016/s0140-6736(76)90090-8

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  13 in total

Review 1.  ATP-sensitive potassium channels and myocardial ischemia: why do they open?

Authors:  W A Coetzee
Journal:  Cardiovasc Drugs Ther       Date:  1992-06       Impact factor: 3.727

2.  Mechanisms contributing to malignant dysrhythmias induced by ischemia in the cat.

Authors:  P B Corr; F X Witkowski; B E Sobel
Journal:  J Clin Invest       Date:  1978-01       Impact factor: 14.808

3.  The role of cyclic adenosine monophosphate in adrenergic effects on ventricular vulnerability to fibrillation in the isolated perfused rat heart.

Authors:  W F Lubbe; T Podzuweit; P S Daries; L H Opie
Journal:  J Clin Invest       Date:  1978-05       Impact factor: 14.808

Review 4.  Should calcium antagonists be used after myocardial infarction? Ischemia selectivity versus vascular selectivity.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1992-02       Impact factor: 3.727

5.  The relationship between coronary artery occlusion-induced arrhythmias and myocardial cyclic nucleotide levels in the anaesthetized rat.

Authors:  K A Kane; E J Morcillo-Sanchez; J R Parratt; I W Rodger; M Shahid
Journal:  Br J Pharmacol       Date:  1985-01       Impact factor: 8.739

6.  Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. A meta-analysis.

Authors:  P Nony; J P Boissel; M Lievre; A Leizorovicz; M C Haugh; S Fareh; B de Breyne
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

7.  The interaction of calcium and cAMP and the relationship to ventricular vulnerability.

Authors:  F T Thandroyen; L M Higginson; L H Opie
Journal:  Basic Res Cardiol       Date:  1981 Jul-Aug       Impact factor: 17.165

8.  Cyclic AMP mediated arrhythmias induced in the ischaemic pig heart.

Authors:  T Podzuweit; D J Els; J McCarthy
Journal:  Basic Res Cardiol       Date:  1981 Jul-Aug       Impact factor: 17.165

Review 9.  Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure.

Authors:  A Fitton; R N Brogden
Journal:  Drugs Aging       Date:  1994-05       Impact factor: 3.923

10.  An endogenous protectant effect of cardiac cyclic GMP against reperfusion-induced ventricular fibrillation in the rat heart.

Authors:  R Pabla; P Bland-Ward; P K Moore; M J Curtis
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.